Browse CD1C

Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Endosome membrane Single-pass type I membrane protein. Lysosome Note=Subject to intracellular trafficking between the cell membrane and endosomes.
Domain PF07654 Immunoglobulin C1-set domain
PF16497 MHC-I family domain
Function

Antigen-presenting protein that binds self and non-self lipid and glycolipid antigens and presents them to T-cell receptors on natural killer T-cells.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002475 antigen processing and presentation via MHC class Ib
GO:0007159 leukocyte cell-cell adhesion
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0042110 T cell activation
GO:0048003 antigen processing and presentation of lipid antigen via MHC class Ib
GO:0048007 antigen processing and presentation, exogenous lipid antigen via MHC class Ib
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
Molecular Function GO:0003823 antigen binding
GO:0030881 beta-2-microglobulin binding
GO:0030882 lipid antigen binding
GO:0030883 endogenous lipid antigen binding
GO:0030884 exogenous lipid antigen binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0051861 glycolipid binding
GO:0071723 lipopeptide binding
Cellular Component GO:0010008 endosome membrane
GO:0044440 endosomal part
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD1C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD1C and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27325645MelanomaInhibit immunity (T cell function)Here we report the identification of a novel BDCA1(+)CD14(+) population of immunosuppressive myeloid cells that are expanded in melanoma patients and are present in dendritic cell-based vaccines, where they suppress CD4(+) T cells in an antigen-specific manner. Mechanistic investigations showed that BDCA1(+)CD14(+) cells expressed high levels of the immune checkpoint molecule PD-L1 to hinder T-cell proliferation.
24935257leukemiaPromote immunity (T cell function); increase the efficacy of immunotherapymLPA-specific T cells efficiently kill CD1c(+) acute leukemia cells, poorly recognize nontransformed CD1c-expressing cells, and protect immunodeficient mice against CD1c(+) human leukemia cells.
24895997melanomaPromote immunity (T cell function); increase the efficacy of immunotherapyThey are activated by a host of ligands including stress-induced self-antigens, glycolipids presented by CD1c/d, and potentially many others that currently remain unidentified.
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD1C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD1C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3220.444
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8090.24
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0360.951
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2280.69
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6510.588
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3030.823
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4580.485
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.710.462
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2070.839
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0550.949
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3370.762
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.8750.000561
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD1C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277309.6-9.60.185
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD1C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD1C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD1C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD1C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD1C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD1C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD1C
NameCD1c molecule
Aliases CD1C antigen, c polypeptide; CD1c antigen; BDCA1; R7; cortical thymocyte antigen CD1C; CD antigen CD1c; T-ce ......
Chromosomal Location1q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD1C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.